13F Holdings
中文EN

BIOE Bio Essence Corp

Pharmaceutical Preparations · OTC · SEC CIK 1723059 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY435.2%
TTM net income YoY943.9%
TTM EPS YoY—
Revenue 3-yr CAGR46.9%
Net income 3-yr CAGR—

Margins

Gross margin68.4%
Operating margin45.1%
Net margin44.7%
FCF margin—
EBITDA margin54.3%

Returns

ROE—
ROA64.7%
ROIC (approx.)—
Asset turnover1.45x

Leverage & solvency

Liabilities / assets42.7%
Debt / equity0.02x
Current ratio0.17x
Interest coverage-286.41x

Cash quality & payout

Operating cash flow / net income0.38x
Accruals ratio39.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$1.90M$323,940$551,506$621,590$887,984
Cost of revenue$469,153$106,863$274,060$293,264$589,660
Gross profit$1.43M$217,077$277,446$328,326$298,324
SG&A expense$497,809$676,515$345,590$763,146$1.08M
Operating income$900,011-$459,438-$345,590-$511,138-$857,527
Interest expense$2,186$2,153$2,197$14,131$38,558
Pretax income$896,997-$1.56M-$403,004-$525,384-$644,264
Income tax$800$800$1,600$2,500$3,300
Net income$896,197-$1.31M-$971,879-$809,679-$647,564
EBITDA$900,246-$458,527-$340,797-$496,625-$821,725
EPS (basic)—-0.03-0.03-0.02-0.02
EPS (diluted)—-0.03-0.03-0.02-0.02
Weighted avg. shares (diluted)38.01M38.01M35.95M33.01M33.01M
Banking
Deposits———$41,841$41,841
Balance sheet
Cash & equivalents—$1,371$114$6,262$303
Receivables$23,454$5,124$35,093$5,599$16,820
Inventory——$143,259$181,163$212,969
Current assets$422,377$280,692$300,000$203,831$261,962
PP&E, net——$3,688$246,379$180,909
Intangibles$97$332$567$802$1,037
Total assets$422,474$281,024$2.76M$1.55M$1.70M
Current liabilities$2.44M$2.80M$2.45M$3.56M$2.76M
Long-term debt$57,482$56,481———
Total debt$57,482$56,481———
Total liabilities$2.50M$3.25M$4.42M$4.79M$4.13M
Shareholders' equity-$2.07M-$2.97M-$1.66M-$3.24M-$2.43M
Net debt—$55,110———
Shares outstanding38.01M38.01M38.01M33.01M33.01M
Cash flow statement
Operating cash flow$1.57M$623,865-$1.03M-$703,241-$1.29M
Capital expenditure——$3,614$3,742$119,496
Free cash flow——-$1.03M-$706,983-$1.41M
Investing cash flow—-$114-$91,484-$59,120-$116,796
Financing cash flow-$1.57M-$622,494$1.11M$768,320$1.41M
Depreciation & amortization$235$911$4,793$14,513$35,802

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.